Cancer Action Network: Rhode Island Senate Votes to Remove Barriers to Biomarker Testing
Dubbed 'the right treatment, to the right patient, at the right time,' precision medicine has played a critical role in improving cancer outcomes - biomarker testing being one of the ways we can achieve these outcomes by allowing doctors to understand and target unique markers in a patient's cancer cells. Despite its benefits, access to biomarker testing has not kept pace with the rate of innovation due in part to lack of coverage by private health insurance and Medicaid for needed testing.
Senate Bill 2201 aims to enable more Rhode Islanders to benefit from biomarker testing, a critical step in accessing precision medicine treatments. The bill now heads to the House.
The following is a statement from
"Biomarker testing and precision medicine are helping extend and improve lives by tailoring care and treatment to a person's individual condition. Over the past many months, we have heard countless stories of the difficulties a patient may face in attempting to access this important testing. It's time for that to change.
"This legislation will help dismantle barriers and bring the promise of precision medicine to cancer patients no matter their income, race or where they live. This would provide many benefits to patients including better outcomes, improved quality of life, and in some cases, reduced costs from bypassing ineffective therapies.
"ACS CAN thanks Senate Majority
As You Sow Foundation: Majority of Chubb Shareholders Support 1.5 c Emissions Reduction Proposal
National Association of Insurance and Financial Advisors: New Rule Strengthens Protections for South Carolina Annuity Consumers
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News